Back to results
US 11,034,657 B2Granted
Liver X receptor (LXR) modulators
AssigneeEllora Therapeutics, Inc.
InventorRaju Mohan
Life of this patent
Estimating the term…
Abstract
Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
Claims18
A compound of Formula (II):
- or a pharmaceutically acceptable salt thereof, wherein:
- X is —C(R6)═C(R6)—;
- L1 is a bond or C1-C6alkyl;
- R1 is —OR9, —N(R9)2, C1-C6alkenyl, C2-C6haloalkyl, C2-C9heterocycloalkyl, —C(═O)R8, or —C(═O)N(R9)2;
- R2 is C1-C6alkyl, C2-C6alkenyl, C3-C8cycloalkyl, or —C1-C6alkyl-C3-C8cycloalkyl;
- R3 is hydrogen, halogen, C1-C6alkyl, or C1-C6haloalkyl;
- R4 is phenyl substituted with at least one R11, wherein at least one R11 is —NR10SO2R10, —SOR10, —SO2R10, or —SO2N(R10)2;
- each R5 is independently halogen, C1-C6alkyl, or C1-C6haloalkyl;
- each R6 is hydrogen;
- R8 is C1-C6alkyl, C2-C6alkenyl, C1-C6haloalkyl, —C1-C6 alkyl-aryl, aryl, or heteroaryl;
- each R9 is independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, C1-C6haloalkyl, —C1-C6 alkyl-aryl, aryl, or heteroaryl;
- each R10 is independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, —C1-C6 alkyl-aryl, aryl, or heteroaryl;
- each R11 is independently halogen, nitro, —OR10, —N(R10)2, —CN, —C(═O)R10, —C(═O)OR10, —C(═O)N(R10)2, —NR10C(═O)R10, NR10SO2R10, —SOR10, —SO2R10, —SO2N(R10)2, —C(═O)OCH2SCH3, optionally substituted C1-C6alkyl, optionally substituted C3-C8cycloalkyl, optionally substituted C1-C6haloalkyl, optionally substituted C1-C6heteroalkyl, optionally substituted —C1-C6 alkyl-aryl, optionally substituted aryl, or optionally substituted heteroaryl;
- and
- n is 0-2.
12 more elements
Dependencies are inferred from the claim text.